3PC-066 Compounding an eye drop formulation of topical insulin for corneal defects refractory to previous treatment: experience in real clinical practice

Abstract

samples. An important increase in the number of isoforms even with changes in their masses, including the main isoform, was detected. Conclusion and relevance Exposure to light may cause modifications in the nivolumab isoform profile which suggests protein degradation. This work shows the importance of protecting opened vials of the medicine Opdivo from light (and by extension, bags for infusion) when they are at room temperature (up to 25°C).

Topical insulin for refractory persistent corneal epithelial defects

“…In the last few years, novel non-invasive treatments including topical epidermal and insulin-like growth factors, topical fibronectin, autologous serum eye drops, and other hemoderivative products have demonstrated promising safety and efficacy in treating PEDs in several clinical trials [6][7][8][9] . Accordingly, topical insulin, a peptide hormone closely related to IGFs, has also shown to be a reliable and effective therapeutic modality for human ocular use in the setting of refractory corneal epithelial wound healing 10,11 . Despite the presence of insulin and its receptors in the human tear film and corneal epithelium, as well as the reported benefits such as convenient administration, high tolerability, and reduced complications in animal experiments, there is a limited number of prospective outcome studies that have examined the mechanisms by which topical insulin promotes the healing PEDs in humans [12][13][14]…”